HealthPathways updated advice for 2022 ’flu jab
The HealthPathways team has recently updated the Influenza Immunisation HealthPathway with the latest information for 2022. The pathway stresses the importance of immunisation against influenza and includes links to key advice and information. ‘There’s a concern that with the reopening of international borders, we will see a surge of influenza as the winter flu from
It’s Worth the Shot – brief intervention training
A new training package is available to help support vaccination providers with shared decision-making for COVID-19 vaccination. The ‘Its Worth the Shot’ package provides new resources to guide meaningful conversations and improve confidence with patients who need more information about vaccination. The package was developed by the Consumers Health Forum of Australia in collaboration with
Influenza vaccination 2022
The Australian Technical Advisory Group on Immunisation (ATAGI) has released clinical advice on season influenza vaccines for 2022. Key points Vaccination is recommended each season for everyone aged 6 months and older. Influenza vaccine and a dose of COVID-19 vaccine can be administered on the same day. As international borders open, seasonal influenza virus may
Dr Austin May to talk hypertension
Join Dr Austin May as he facilitates a conversation on hypertension management in the primary care setting. With Dr Stephen Moore, Neil Chapman and Carolyn Davis. Hypertension is a significant threat to population health. Globally, high blood pressure is directly linked to more than 8.5 million deaths every year.* Hypertension is consistently one of the
Pfizer’s COVID-19 vaccine provisionally approved as booster for young people aged 16 and 17
The Therapeutic Goods Administration (TGA) has provisionally approved the Pfizer COVID-19 vaccine as a booster for young people aged 16 and 17 years old. Dosing in this age group is the same as the adult population – a booster dose may be administered intramuscularly after the completion of a COVID-19 vaccine primary series (2 doses).
ATAGI statement on the use of Novavax COVID-19 vaccine
Novavax COVID-19 vaccine, also known as Nuvaxovid, has been provisionally approved by the Therapeutic Goods Administration for use in a primary course of vaccination in people aged 18 years and older. Following this approval, the Australian Technical Advisory Group on Immunisation (ATAGI) has published recommendations on the use of Nuvaxovid. In addition, the Australian Government Department
Fourth COVID-19 vaccine approved
The Therapeutic Goods Administration (TGA) has given approval for a fourth COVID-19 vaccine. The Novavax vaccine will be available to people 18 years and over. It will be given in 2 doses, 3 weeks apart. The Novavax vaccine is a protein subunit vaccine. Protein vaccines use a non-infectious component of the coronavirus. After vaccination, immune
Holiday arrangements for ordering COVID-19 vaccines
With the holiday season fast approaching, practices should begin planning for the number of COVID-19 vaccines needed from mid-to-late December 2021 to mid-January 2022. When ordering, consider the additional stock and consumables needed to meet demand over the holiday period. The table below provides key dates for ordering and deliveries over the Christmas/New Year period.
TGA provisionally approves Pfizer COVID-19 vaccine for 5 to 11-year-olds
The Therapeutic Goods Administration (TGA) has provisionally approved the Comirnaty Paediatric (Pfizer) COVID-19 vaccine for 5 to 11-year-olds. The TGA’s provisional approval of the vaccine was based on a careful evaluation of available data to support its safety and efficacy among this age group. The paediatric vaccine dose is one-third the size approved for people
Are your patients eligible for home COVID-19 vaccination?
A nurse immuniser from the Northern NSW Local Health District can now visit eligible people in their homes to give a COVID-19 vaccine. Your patients may be eligible if they: have an injury, long-term health issue or condition that makes it hard for them to move around or leave home have a disability are a
Changes to the National Cervical Screening Program announced
Women eligible for a screening test under the National Cervical Screening Program (NCSP) will be able to self-collect their own screening sample (accessed through their primary healthcare provider) from 1 July 2022. Self-collection was originally introduced in December 2017 as part of the renewed NCSP, but access is currently restricted to: women who have never
Course in vaccinology and immunisation science
The Peter Doherty Institute for Infection and Immunity and the National Centre for Immunisation Research and Surveillance (NCIRS) are offering a course in vaccinology and immunisation science. This practical online course is for people relatively new to vaccines and for those wanting to broaden and update their understanding of vaccines, vaccine development and the principles
